ACRMEDIUM SIGNALFINANCIAL10-K

ACR's commercial real estate lending activity expanded meaningfully while profitability metrics deteriorated due to rising financing costs and substantially reduced operating cash flow generation.

The company significantly increased its CRE loan origination activity from one loan worth $47.9 million in 2024 to 15 loans totaling $757.3 million in 2025, demonstrating aggressive growth in lending operations. However, this expansion came at the cost of profitability, with interest expenses rising substantially while net interest income declined 24.2%, suggesting margin compression in a challenging rate environment.

Comparing 2026-03-10 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

ACR's balance sheet expanded with total assets growing 14.9% to $2.2 billion and debt increasing 13.3% to $1.6 billion, reflecting the company's growth strategy in commercial real estate lending. However, profitability metrics weakened considerably, with net interest income declining 24.2% as interest expenses rose substantially, indicating pressure on lending margins. Most concerning, operating cash flow fell dramatically from $19.4 million to $4.1 million, suggesting the business model is generating significantly less cash despite the larger asset base.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-78.8%
$19.4M→$4.1M

Operating cash flow fell 78.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
+58.9%
$82.3M→$130.8M

Interest expense surged 58.9% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+47.7%
$56.7M→$83.8M

Cash position surged 47.7% — strong cash generation or capital raise providing significant financial cushion.

Net Interest Income
P&L
-24.2%
$157.3M→$119.1M

Net interest income declined 24.2% — margin compression from rate changes or funding cost increases.

Total Assets
Balance Sheet
+14.9%
$1.9B→$2.2B

Asset base grew 14.9% — expansion through organic growth, acquisitions, or capital deployment.

Total Debt
Balance Sheet
+13.3%
$1.4B→$1.6B

Debt rose 13.3% — additional borrowing for investment or operations; monitor coverage ratios.

Total Liabilities
Balance Sheet
+12.6%
$1.4B→$1.6B

Liabilities increased 12.6% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-17
ADDED
The number of outstanding shares of the registrant s common stock on March 6, 2026 was 7,131,101 shares.
During the year ended December 31, 2025, we originated 15 CRE loans with total commitments of $757.3 million.
At December 31, 2025, our CRE loan portfolio at par comprised $1.8 billion of CRE whole loans with a weighted average spread of 3.35% over the one-month benchmark interest rates utilized, which have a weighted average floor of 1.78%.
We are currently invested in CRE whole loans and CRE equity investments.
At December 31, 2025, our financing arrangements were as follows (in thousands): Outstanding Borrowings (1) Value of Collateral Equity at Risk (2) At December 31, 2025: CRE - Term Reinvestment Financing Facility JPMorgan Chase Bank, N.A.
$ 728,167 $ 1,009,622 $ 295,734 Senior Secured Financing Facility Massachusetts Mutual Life Insurance Company $ 61,645 $ 166,526 $ 104,091 CRE -Term Warehouse Financing Facilities JPMorgan Chase Bank, N.A.
$ 116,488 $ 149,000 $ 32,570 Morgan Stanley Mortgage Capital Holdings LLC $ 417,374 $ 544,937 $ 130,295 Mortgage Payable ReadyCap Commercial, LLC $ 20,185 $ 26,964 $ 6,695 Total $ 1,343,859 $ 1,897,049 (1) Includes deferred debt issuance costs.
Our financing arrangements charge a floating rate of interest.
(Back to Index) 6 (Back to Index) Credit and risk management policies.
At December 31, 2025, 76.5% of the par value of our CRE loan portfolio had interest rate caps with a weighted-average maturity of 15 months or funded debt service reserves in place.
REMOVED
The number of outstanding shares of the registrant s common stock on March 13, 2025 was 7,456,150 shares.
During the year ended December 31, 2024, we selectively originated one CRE loan with a total commitment of $47.9 million.
At December 31, 2024, our CRE loan portfolio at par comprised $1.5 billion of CRE whole loans with a weighted average spread of 3.73% over the one-month benchmark interest rates utilized, which have a weighted average floor of 0.97%.
Additionally, our CRE loan portfolio included one fully reserved $4.7 million mezzanine loan at December 31, 2024.
We are currently invested in CRE whole loans, CRE mezzanine loans and CRE equity investments.
At December 31, 2024, we managed $1.9 billion of assets, including $1.1 billion of assets that were financed and held in variable interest entities.
At December 31, 2024, our financing arrangements were as follows (in thousands): Outstanding Borrowings (1) Value of Collateral Equity at Risk (2) At December 31, 2024: CRE Securitizations ACR 2021-FL1 $ 471,847 $ 599,927 $ 127,420 ACR 2021-FL2 390,957 525,571 133,000 Senior Secured Financing Facility Massachusetts Mutual Life Insurance Company $ 60,910 $ 162,578 $ 99,899 CRE -Term Warehouse Financing Facilities JPMorgan Chase Bank, N.A.
$ 90,995 $ 158,639 $ 67,802 Morgan Stanley Mortgage Capital Holdings LLC 65,744 98,373 33,566 Mortgages Payable ReadyCap Commercial, LLC $ 20,240 $ 26,960 $ 6,566 Oceanview Life and Annuity Company (3) 44,211 92,549 31,809 Florida Pace Funding Agency (3) 15,105 Total $ 1,160,009 $ 1,664,597 (1) CRE securitizations, senior secured financing facility and mortgages payable include deferred debt issuance costs.
Term warehouse financing facilities include accrued interest payable and deferred debt issuance costs.
CRE securitizations reflect the par value of equity investments in retained notes.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →